SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as investors aggressively accumulate on dips, driven by anticipation surrounding the Clarity Act and ongoing institutional partnerships with major financial players. The community remains divided between long-term holders focusing on real-world payroll utility and skeptics reacting to daily price volatility and past performance.

Allora is a decentralized intelligence network that makes artificial intelligence more adaptive, collaborative, and efficient. The platform combines and coordinates thousands of specialized AI models in real time to produce superior inferences for users and applications. By enabling anyone to contribute models, data, or validation, Allora creates a self-improving market for intelligence that powers agents, DeFi systems, and AI applications across chains.

Allora

Allora is generating significant interest as traders debate its momentum and potential for a short squeeze following recent exchange volatility. Community sentiment remains polarized, with many highlighting the coin's low circulating supply and upcoming project announcements as key drivers for potential upside.

Canton Coin (CC), the network’s native utility token, was designed to reward real network usage over speculation. It aligns the success of the network with the participants who make it work, fairly rewarding app builders and app users, as well as those operating decentralized infrastructure. The result is a fundamentally different model where rewards flow to those creating value through real activity, not only miners or early investors.

Canton

Canton Network is gaining significant traction as a key infrastructure project for institutional finance, with major global payment companies joining as validators. The community is actively discussing its long-term potential in tokenized asset settlement, while closely monitoring token supply dynamics and exchange listing momentum.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Aerodrome Finance is attracting significant attention as investors anticipate its expansion to the Ethereum mainnet and a potential broader market recovery. The community is actively discussing its role as a key liquidity hub on the Base chain, with many debating the sustainability of its token emissions model versus its potential for explosive growth.

DEGEN is a reward token for Farcaster users, born from meme culture. It features a unique tipping system that allows the community to reward high-quality content creators. DEGEN also powers the Degen Chain, one of the pioneering Layer 3s launched on Base. Known as the “Las Vegas of blockchains,” it provides a platform for building and using Degen apps, offering a space for fun, innovation, and community-driven experiences.

Degen

DEGEN is capturing community attention as investors discuss potential ecosystem expansion, including new app developments and token burn initiatives aimed at boosting value. While some participants express caution regarding market volatility and previous price action, many are focused on the project's long-term utility and potential for broader exchange exposure.

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the following segments: Platform and Devices. The Platform segment includes the sale of digital advertising and distribution of streaming services. The Devices segment is involved in the sale of streaming players, Roku-made televisions, smart home products and services, audio products, and related accessories. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Roku is attracting intense investor interest as market participants speculate on potential acquisition interest and a short squeeze triggered by S&P index inclusion, while analysts highlight improved profitability and platform growth as core catalysts. The community is actively debating the company's valuation, questioning if the platform's long-term advertising and subscription momentum justifies a major breakout from current price levels.

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Kyverna Therapeutics Inc.

Kyverna Therapeutics is trending following positive registrational trial data for its CAR-T therapy miv-cel in Stiff Person Syndrome, with investors actively discussing its potential as a first-in-class treatment and a primary target for future M&A. The community is focused on the therapy's ability to drive durable, drug-free remission in refractory autoimmune patients, while also monitoring the company's capital allocation and broader pipeline expansion.

Domino's Pizza, Inc. engages in the management of a network of company-owned and franchise-owned pizza stores. It operates through the following segments: U.S. Stores, International Franchise, and Supply Chain. The U.S. Stores segment consists primarily of franchise operations. The International Franchise segment comprises a network of franchised stores. The Supply Chain segment manages regional dough manufacturing and food supply chain centers. The company was founded by James Monaghan and Thomas Stephen Monaghan in 1960 and is headquartered in Ann Arbor, MI.

Dominos Pizza Inc

Dominos Pizza is facing intense investor scrutiny as it navigates a challenging restaurant landscape defined by sluggish consumer discretionary spending and aggressive industry-wide price wars. Community discourse remains divided between those betting on long-term value through menu innovation and digital delivery partnerships and skeptics who fear the brand is losing its competitive edge to local rivals and shifting health trends.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following a late-breaking abstract presentation of Phase 2 axSpA data at the EULAR congress, which the community is interpreting as a 'best-in-class' signal. Investors are actively discussing the upcoming 52-week VELA trial results and the company's participation in the Goldman Sachs Healthcare Conference as critical catalysts that could drive a significant re-rating or trigger acquisition interest.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is experiencing a surge in community engagement and price speculation, driven by anticipation of upcoming network upgrades and potential large-scale token burns. Traders and long-term holders are actively discussing recovery narratives and market momentum, with many looking toward the projects future potential despite past volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kura Oncology (KURA) Reports Q1 Loss, Tops Revenue Estimates

Kura Oncology (KURA) delivered earnings and revenue surprises of +5.33% and +21.30%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates

Celldex (CLDX) delivered earnings and revenue surprises of -6.88% and -98.87%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Will MeiraGTx Holdings PLC (MGTX) Report Negative Q1 Earnings? What You Should Know

MeiraGTx (MGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kura Oncology (KURA) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Kura Oncology (KURA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kura Oncology (KURA) Projected to Post Quarterly Earnings on Thursday

Kura Oncology (NASDAQ:KURA) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-kura-oncology-inc-stock...

Moody Aldrich Partners LLC Buys New Position in Kura Oncology, Inc. $KURA

Moody Aldrich Partners LLC bought a new stake in shares of Kura Oncology, Inc. (NASDAQ:KURA - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 179,728 shares of the company's s...

KURA Stock Rallies 8% on Strong Preliminary Renal Cancer Study Data

Kura Oncology shares jump 8% as FIT-001 data show strong tumor response and disease control with darlifarnib combination in pretreated renal cancer patients.

Kura Oncology (KURA) Moves 8.3% Higher: Will This Strength Last?

Kura Oncology (KURA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Kura Oncology, Inc. (NASDAQ:KURA) Given Average Recommendation of "Moderate Buy" by Brokerages

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) has received an average recommendation of "Moderate Buy" from the thirteen brokerages that are currently covering the stock, MarketBeat reports...

Kura Oncology (NASDAQ:KURA) Stock Price Up 9.7% - Time to Buy?

Kura Oncology (NASDAQ:KURA) Trading Up 9.7% - Here's What Happened...

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Current Price	$8.74
Prev Close	$8.77
Open	$8.76
Dividend Yield	0.00%
50-Day Moving Average	$9.20
Beta	1.15
Avg. Volume	1.93M
PE Ratio	-2.61

52-Week High	$12.49
52-Week Low	$5.45
Market Capitalization	$775.89M
EPS (Annual)	-$3.18
Price to Book	7.19
Revenue Per Employee	$259,546.15

KURAKura Oncology Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest KURA News